FCRN inhibitor sales: Vyvgart dominates market

Argenx continues to build its dominant commercial position in the FCRN market thanks not only to its first-mover advantage but quick expansion into new indications.

For 2024, Argenx SE (Euronext:ARGX; NASDAQ:ARGX) reported $2.2 billion in sales of FCRN inhibitor Vyvgart efgartigimod, an increase of 84% vs. $1.2 billion in 2023...